Canaccord Genuity analyst John Newman maintained a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) Inc on Wednesday, setting a price target of $55, which is approximately 15.89% above the present share price of $47.46.
Newman expects Allogene Therapeutics Inc to post earnings per share (EPS) of -$0.50 for the second quarter of 2020.
The current consensus among 13 TipRanks analysts is for a Strong Buy rating of shares in Allogene Therapeutics, with an average price target of $53.18.
The analysts price targets range from a high of $70 to a low of $32.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$57.68 million. The company's market cap is $5.81 billion.
According to TipRanks.com, Canaccord Genuity analyst John Newman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.6% and a 46.51% success rate.
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.